NASDAQ:HTGM - HTG Molecular Diagnostics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.31 +0.14 (+4.42 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$3.24
Today's Range$3.21 - $3.33
52-Week Range$1.59 - $5.83
Volume3,664 shs
Average Volume302,980 shs
Market Capitalization$89.78 million
P/E Ratio-1.81
Dividend YieldN/A
HTG Molecular Diagnostics logoHTG Molecular Diagnostics, Inc. develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's assay product offerings include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq PATH Assay; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq EGFR, KRAS, and BRAF mutation assay; HTG EdgeSeq ALKPlus assay EU; and HTG EdgeSeq DLBCL cell of origin assay EU. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a collaboration agreement with Bristol-Myers Squibb for the development of custom RUO assays; master collaboration agreement with Merck KGaA; governing agreement with QIAGEN Manchester Limited; and development and professional services agreement with Invetech PTY Ltd. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.

Receive HTGM News and Ratings via Email

Sign-up to receive the latest news and ratings for HTGM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Analytical instruments


Debt-to-Equity Ratio0.31
Current Ratio9.80
Quick Ratio9.59


Trailing P/E Ratio-1.81
Forward P/E Ratio-4.53
P/E GrowthN/A

Sales & Book Value

Annual Sales$14.76 million
Price / Sales6.37
Cash FlowN/A
Price / CashN/A
Book Value($0.12) per share
Price / Book-27.58


EPS (Most Recent Fiscal Year)($1.79)
Net Income$-18,960,000.00
Net Margins-105.56%
Return on Equity-338.96%
Return on Assets-66.49%


Outstanding Shares28,410,000
Market Cap$89.78

HTG Molecular Diagnostics (NASDAQ:HTGM) Frequently Asked Questions

What is HTG Molecular Diagnostics' stock symbol?

HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."

How were HTG Molecular Diagnostics' earnings last quarter?

HTG Molecular Diagnostics Inc (NASDAQ:HTGM) issued its quarterly earnings results on Thursday, May, 10th. The medical research company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.04. The medical research company earned $4.16 million during the quarter, compared to the consensus estimate of $5.24 million. HTG Molecular Diagnostics had a negative return on equity of 338.96% and a negative net margin of 105.56%. View HTG Molecular Diagnostics' Earnings History.

What price target have analysts set for HTGM?

3 equities research analysts have issued 1 year target prices for HTG Molecular Diagnostics' shares. Their predictions range from $7.00 to $7.00. On average, they anticipate HTG Molecular Diagnostics' stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 111.5% from the stock's current price. View Analyst Ratings for HTG Molecular Diagnostics.

What is the consensus analysts' recommendation for HTG Molecular Diagnostics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HTG Molecular Diagnostics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of HTG Molecular Diagnostics' key competitors?

Who are HTG Molecular Diagnostics' key executives?

HTG Molecular Diagnostics' management team includes the folowing people:
  • Mr. Timothy B. Johnson, CEO & Director (Age 57)
  • Mr. John L. Lubniewski, Pres & COO (Age 54)
  • Mr. Shaun D. McMeans, Sr. VP and CFO (Age 56)
  • Dr. Debra A. Gordon, Sr. VP and Chief Legal Counsel (Age 58)
  • Dr. Patrick C. Roche, Sr. VP of R&D (Age 65)

When did HTG Molecular Diagnostics IPO?

(HTGM) raised $50 million in an initial public offering on Wednesday, May 6th 2015. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. Leerink Partners acted as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Has HTG Molecular Diagnostics been receiving favorable news coverage?

Media stories about HTGM stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. HTG Molecular Diagnostics earned a daily sentiment score of 0.15 on Accern's scale. They also gave media coverage about the medical research company an impact score of 45.46 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of HTG Molecular Diagnostics?

Shares of HTGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is HTG Molecular Diagnostics' stock price today?

One share of HTGM stock can currently be purchased for approximately $3.31.

How big of a company is HTG Molecular Diagnostics?

HTG Molecular Diagnostics has a market capitalization of $89.78 million and generates $14.76 million in revenue each year. The medical research company earns $-18,960,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis. HTG Molecular Diagnostics employs 98 workers across the globe.

How can I contact HTG Molecular Diagnostics?

HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The medical research company can be reached via phone at 877-289-2615.

MarketBeat Community Rating for HTG Molecular Diagnostics (NASDAQ HTGM)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  177 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  331
MarketBeat's community ratings are surveys of what our community members think about HTG Molecular Diagnostics and other stocks. Vote "Outperform" if you believe HTGM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HTGM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.